by Dale Harrison | Dec 25, 2015 | Publications
“Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer” American Society of Cell Biology Annual Meeting, December 2015 Authors D. Elzi, PhD, UTHSCSA; P. Fatland, UTHSCSA; B....
by Maria Zannes | Dec 16, 2015 | News
DECEMBER 16, 2015 As published in the San Antonio Business Journal By W. Scott Bailey The People’s Republic of China has awarded a Certificate of Invention Patent to bioAffinity Technologies for its proprietary CyPath® assay, which could have a profound impact on...
by Maria Zannes | Dec 14, 2015 | Press Releases
DECEMBER 14, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies announced the People’s Republic of China awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that preferentially binds to cancer cells and labels them a...
by Maria Zannes | Dec 14, 2015 | Events
DECEMBER 14, 2015 Poster presented by David Elzi, PhD The University of Texas Health Science Center San Antonio Dr. Elzi is a member of the research collaboration team from the UT Health Science Center and bioAffinity Technologies. American Society for Cell...
by Maria Zannes | Dec 10, 2015 | Press Releases
DECEMBER 10, 2015 SAN ANTONIO–(BUSINESS WIRE)–The porphyrin compound used in bioAffinity Technologies’ proprietary CyPath® Lung is a novel marker for endocytosis, new research shows. Endocytosis is a process that is often disrupted in cancer. The finding will be...
